Point-of-Care Coagulation Testing Devices Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Description
Growth Factors of point-of-care coagulation (POCC) testing devices Market
The global point-of-care coagulation (POCC) testing devices market has emerged as a critical segment within diagnostic technologies due to the increasing need for rapid and accurate coagulation assessment. These devices enable clinicians to evaluate a patient’s coagulation status in real time, supporting timely clinical decisions in emergency care, surgical procedures, and anticoagulation therapy monitoring.
According to the report, the global POCC testing devices market was valued at USD 2.01 billion in 2025. The market is projected to expand to USD 2.16 billion in 2026 and further reach USD 3.88 billion by 2034, registering a compound annual growth rate (CAGR) of 7.62% during the forecast period from 2026 to 2034. This growth is primarily driven by the rising prevalence of bleeding disorders, technological advancements in point-of-care diagnostics, and increasing adoption of home-based healthcare solutions.
Market Drivers and Growth Factors
One of the key drivers fueling market growth is the increasing patient pool suffering from bleeding disorders, including hemophilia, venous thromboembolism, and coagulation abnormalities associated with aging. The growing geriatric population is particularly vulnerable to coagulation imbalance, thereby increasing demand for portable and easy-to-use testing devices.
In addition, technological advancements in POCC testing devices have significantly improved accuracy, usability, and turnaround time. Market players are launching advanced systems capable of delivering rapid results at the bedside or in homecare settings. The rising demand for home healthcare solutions has further accelerated adoption, as patients undergoing long-term anticoagulation therapy prefer self-monitoring devices to avoid frequent hospital visits.
Another contributing factor is the improvement in healthcare infrastructure in emerging markets, where governments are investing heavily in expanding diagnostic services, especially in community healthcare centers and small clinics.
Market Restraints and Challenges
Despite strong growth prospects, the market faces notable challenges. The high cost of POCC testing devices, along with recurring expenses related to maintenance and consumables, restricts adoption in price-sensitive and emerging economies. Limited reimbursement policies and stringent regulatory requirements for home-based testing devices also hinder market penetration.
Furthermore, competition from traditional laboratory coagulation testing remains a challenge, as conventional analyzers are widely trusted for their comprehensive testing capabilities. A lack of awareness and insufficient training among healthcare professionals regarding the correct use of POCC devices can also lead to underutilization and misinterpretation of results.
Segmentation Insights
By device type, anticoagulation monitoring devices dominated the market, accounting for 79.64% of the total market share in 2026, supported by increasing regulatory approvals and widespread use in monitoring PT/INR levels. Meanwhile, viscoelastic coagulation monitoring devices are expected to witness the fastest growth during the forecast period due to their ability to assess all stages of clot formation in real time.
By end user, the hospitals and clinics segment led the market with a 63.85% share in 2026, driven by the growing number of complex surgical procedures requiring immediate coagulation assessment. The homecare settings segment is anticipated to grow at the highest CAGR due to rising patient preference for self-monitoring solutions.
Regional Outlook
North America dominated the global market in 2025, accounting for USD 0.85 billion, supported by the strong presence of leading manufacturers, high prevalence of bleeding disorders, and favorable regulatory approvals. Europe held the second-largest share due to the introduction of advanced coagulation analyzers in hospitals. The Asia Pacific region is expected to grow at the highest CAGR, driven by increasing awareness, regulatory approvals, and expanding healthcare infrastructure in countries such as China, India, and Japan.
Competitive Landscape
The market is semi-consolidated, with major players including F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthineers AG, Werfen, Haemonetics Corporation, and Medtronic. These companies focus on strategic collaborations, regulatory approvals, and product innovations to strengthen their market position.
Conclusion
In conclusion, the global point-of-care coagulation (POCC) testing devices market is poised for sustained growth, rising from USD 2.01 billion in 2025 to USD 3.88 billion by 2034. The increasing burden of bleeding disorders, growing demand for rapid diagnostic solutions, and expansion of home-based healthcare are key factors shaping market expansion. While high costs and competition from traditional laboratory testing pose challenges, ongoing technological advancements and strategic initiatives by leading players are expected to enhance adoption and drive long-term market growth across developed and emerging regions.
ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year 2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth rate CAGR of 7.62% from 2026-2034
Unit Value (USD billion)
Segmentation
By Device Type
Anticoagulation Monitoring Devices
Prothrombin Time/International Normalized Ratio (PT/INR) Testing Devices
Activated Clotting Time (ACT)
Activated Partial Thromboplastin Time (aPTT)
Platelet Function Monitoring Devices
Viscoelastic Coagulation Monitoring Devices
Thromboelastography (TEG)
Rotational Thromboelastometry (ROTEM)
Others
By End User
Hospitals & Clinics
Homecare Settings
Others
By Region
North America (by Device Type, by End User, by Country)
Please Note: It will take 2-3 business days to complete the report upon order confirmation.
The global point-of-care coagulation (POCC) testing devices market has emerged as a critical segment within diagnostic technologies due to the increasing need for rapid and accurate coagulation assessment. These devices enable clinicians to evaluate a patient’s coagulation status in real time, supporting timely clinical decisions in emergency care, surgical procedures, and anticoagulation therapy monitoring.
According to the report, the global POCC testing devices market was valued at USD 2.01 billion in 2025. The market is projected to expand to USD 2.16 billion in 2026 and further reach USD 3.88 billion by 2034, registering a compound annual growth rate (CAGR) of 7.62% during the forecast period from 2026 to 2034. This growth is primarily driven by the rising prevalence of bleeding disorders, technological advancements in point-of-care diagnostics, and increasing adoption of home-based healthcare solutions.
Market Drivers and Growth Factors
One of the key drivers fueling market growth is the increasing patient pool suffering from bleeding disorders, including hemophilia, venous thromboembolism, and coagulation abnormalities associated with aging. The growing geriatric population is particularly vulnerable to coagulation imbalance, thereby increasing demand for portable and easy-to-use testing devices.
In addition, technological advancements in POCC testing devices have significantly improved accuracy, usability, and turnaround time. Market players are launching advanced systems capable of delivering rapid results at the bedside or in homecare settings. The rising demand for home healthcare solutions has further accelerated adoption, as patients undergoing long-term anticoagulation therapy prefer self-monitoring devices to avoid frequent hospital visits.
Another contributing factor is the improvement in healthcare infrastructure in emerging markets, where governments are investing heavily in expanding diagnostic services, especially in community healthcare centers and small clinics.
Market Restraints and Challenges
Despite strong growth prospects, the market faces notable challenges. The high cost of POCC testing devices, along with recurring expenses related to maintenance and consumables, restricts adoption in price-sensitive and emerging economies. Limited reimbursement policies and stringent regulatory requirements for home-based testing devices also hinder market penetration.
Furthermore, competition from traditional laboratory coagulation testing remains a challenge, as conventional analyzers are widely trusted for their comprehensive testing capabilities. A lack of awareness and insufficient training among healthcare professionals regarding the correct use of POCC devices can also lead to underutilization and misinterpretation of results.
Segmentation Insights
By device type, anticoagulation monitoring devices dominated the market, accounting for 79.64% of the total market share in 2026, supported by increasing regulatory approvals and widespread use in monitoring PT/INR levels. Meanwhile, viscoelastic coagulation monitoring devices are expected to witness the fastest growth during the forecast period due to their ability to assess all stages of clot formation in real time.
By end user, the hospitals and clinics segment led the market with a 63.85% share in 2026, driven by the growing number of complex surgical procedures requiring immediate coagulation assessment. The homecare settings segment is anticipated to grow at the highest CAGR due to rising patient preference for self-monitoring solutions.
Regional Outlook
North America dominated the global market in 2025, accounting for USD 0.85 billion, supported by the strong presence of leading manufacturers, high prevalence of bleeding disorders, and favorable regulatory approvals. Europe held the second-largest share due to the introduction of advanced coagulation analyzers in hospitals. The Asia Pacific region is expected to grow at the highest CAGR, driven by increasing awareness, regulatory approvals, and expanding healthcare infrastructure in countries such as China, India, and Japan.
Competitive Landscape
The market is semi-consolidated, with major players including F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthineers AG, Werfen, Haemonetics Corporation, and Medtronic. These companies focus on strategic collaborations, regulatory approvals, and product innovations to strengthen their market position.
Conclusion
In conclusion, the global point-of-care coagulation (POCC) testing devices market is poised for sustained growth, rising from USD 2.01 billion in 2025 to USD 3.88 billion by 2034. The increasing burden of bleeding disorders, growing demand for rapid diagnostic solutions, and expansion of home-based healthcare are key factors shaping market expansion. While high costs and competition from traditional laboratory testing pose challenges, ongoing technological advancements and strategic initiatives by leading players are expected to enhance adoption and drive long-term market growth across developed and emerging regions.
ATTRIBUTE DETAILS
Study Period 2021-2034
Base Year 2025
Estimated Year 2026
Forecast Period 2026-2034
Historical Period 2021-2024
Growth rate CAGR of 7.62% from 2026-2034
Unit Value (USD billion)
Segmentation
By Device Type
Anticoagulation Monitoring Devices
Prothrombin Time/International Normalized Ratio (PT/INR) Testing Devices
Activated Clotting Time (ACT)
Activated Partial Thromboplastin Time (aPTT)
Platelet Function Monitoring Devices
Viscoelastic Coagulation Monitoring Devices
Thromboelastography (TEG)
Rotational Thromboelastometry (ROTEM)
Others
By End User
Hospitals & Clinics
Homecare Settings
Others
By Region
North America (by Device Type, by End User, by Country)
- U.S.
- Canada
- U.K.
- Germany
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Japan
- China
- India
- Australia
- Southeast Asia
- Rest of the Asia Pacific
- Brazil
- Mexico
- Rest of Latin America
- GCC
- South Africa
- Rest of the Middle East & Africa
Please Note: It will take 2-3 business days to complete the report upon order confirmation.
Table of Contents
140 Pages
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Autism, By Key Countries, 2025
- 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
- 4.3. Regulatory Framework by Key Countries/Regions
- 4.4. Global Reimbursement Scenario and Economic Cost Burden for the Treatment of Autism Spectrum Disorder by Key Countries/Region
- 4.5. Pipeline Analysis, By Key Players
- 5. Global Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast – By Drug Type
- 5.1.1. Antipsychotic Drugs
- 5.1.2. SSRIs/Antidepressants
- 5.1.3. Stimulants
- 5.1.4. Sleep Medications
- 5.1.5. Others
- 5.2. Market Analysis, Insights and Forecast – By Disease
- 5.2.1. Autistic Disorder
- 5.2.2. Asperger Syndrome
- 5.2.3. Pervasive Developmental Disorder (PDD)
- 5.2.4. Others
- 5.3. Market Analysis, Insights and Forecast – By Age Group
- 5.3.1. Adults
- 5.3.2. Pediatrics
- 5.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 5.4.1. Hospital Pharmacies
- 5.4.2. Drug Stores & Retail Pharmacies
- 5.4.3. Online Pharmacies
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
- 6. North America Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast – By Drug Type
- 6.1.1. Antipsychotic Drugs
- 6.1.2. SSRIs/Antidepressants
- 6.1.3. Stimulants
- 6.1.4. Sleep Medications
- 6.1.5. Others
- 6.2. Market Analysis, Insights and Forecast – By Disease
- 6.2.1. Autistic Disorder
- 6.2.2. Asperger Syndrome
- 6.2.3. Pervasive Developmental Disorder (PDD)
- 6.2.4. Others
- 6.3. Market Analysis, Insights and Forecast – By Age Group
- 6.3.1. Adults
- 6.3.2. Pediatrics
- 6.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 6.4.1. Hospital Pharmacies
- 6.4.2. Drug Stores & Retail Pharmacies
- 6.4.3. Online Pharmacies
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
- 7. Europe Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast – By Drug Type
- 7.1.1. Antipsychotic Drugs
- 7.1.2. SSRIs/Antidepressants
- 7.1.3. Stimulants
- 7.1.4. Sleep Medications
- 7.1.5. Others
- 7.2. Market Analysis, Insights and Forecast – By Disease
- 7.2.1. Autistic Disorder
- 7.2.2. Asperger Syndrome
- 7.2.3. Pervasive Developmental Disorder (PDD)
- 7.2.4. Others
- 7.3. Market Analysis, Insights and Forecast – By Age Group
- 7.3.1. Adults
- 7.3.2. Pediatrics
- 7.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 7.4.1. Hospital Pharmacies
- 7.4.2. Drug Stores & Retail Pharmacies
- 7.4.3. Online Pharmacies
- 7.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
- 8. Asia Pacific Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast – By Drug Type
- 8.1.1. Antipsychotic Drugs
- 8.1.2. SSRIs/Antidepressants
- 8.1.3. Stimulants
- 8.1.4. Sleep Medications
- 8.1.5. Others
- 8.2. Market Analysis, Insights and Forecast – By Disease
- 8.2.1. Autistic Disorder
- 8.2.2. Asperger Syndrome
- 8.2.3. Pervasive Developmental Disorder (PDD)
- 8.2.4. Others
- 8.3. Market Analysis, Insights and Forecast – By Age Group
- 8.3.1. Adults
- 8.3.2. Pediatrics
- 8.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 8.4.1. Hospital Pharmacies
- 8.4.2. Drug Stores & Retail Pharmacies
- 8.4.3. Online Pharmacies
- 8.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
- 9. Latin America Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast – By Drug Type
- 9.1.1. Antipsychotic Drugs
- 9.1.2. SSRIs/Antidepressants
- 9.1.3. Stimulants
- 9.1.4. Sleep Medications
- 9.1.5. Others
- 9.2. Market Analysis, Insights and Forecast – By Disease
- 9.2.1. Autistic Disorder
- 9.2.2. Asperger Syndrome
- 9.2.3. Pervasive Developmental Disorder (PDD)
- 9.2.4. Others
- 9.3. Market Analysis, Insights and Forecast – By Age Group
- 9.3.1. Adults
- 9.3.2. Pediatrics
- 9.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 9.4.1. Hospital Pharmacies
- 9.4.2. Drug Stores & Retail Pharmacies
- 9.4.3. Online Pharmacies
- 9.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
- 10. Middle East & Africa Autism Spectrum Disorder Therapeutics Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast – By Drug Type
- 10.1.1. Antipsychotic Drugs
- 10.1.2. SSRIs/Antidepressants
- 10.1.3. Stimulants
- 10.1.4. Sleep Medications
- 10.1.5. Others
- 10.2. Market Analysis, Insights and Forecast – By Disease
- 10.2.1. Autistic Disorder
- 10.2.2. Asperger's Syndrome
- 10.2.3. Pervasive Developmental Disorder (PDD)
- 10.2.4. Others
- 10.3. Market Analysis, Insights and Forecast – By Age Group
- 10.3.1. Adults
- 10.3.2. Pediatrics
- 10.4. Market Analysis, Insights and Forecast – By Distribution Channel
- 10.4.1. Hospital Pharmacies
- 10.4.2. Drug Stores & Retail Pharmacies
- 10.4.3. Online Pharmacies
- 10.5. Market Analysis, Insights and Forecast – By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
- 11.2.1. Curemark, LLC
- 11.2.2. Yamo Pharmaceuticals
- 11.2.3. Pfizer Inc.
- 11.2.4. Eli Lilly and Company
- 11.2.5. AstraZeneca
- 11.2.6. F. Hoffmann-La Roche Ltd
- 11.2.7. Otsuka Holdings Co. Ltd.
- 11.2.8. Johnson & Johnson Services, Inc.
- 11.2.9. Teva Pharmaceutical Industries Ltd.
- 11.2.10. H. Lundbeck A/S
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
